کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5697651 1601103 2017 33 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
GEIS guidelines for gastrointestinal sarcomas (GIST)
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
GEIS guidelines for gastrointestinal sarcomas (GIST)
چکیده انگلیسی
GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours. Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60 months. Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Treatment Reviews - Volume 55, April 2017, Pages 107-119
نویسندگان
, , , , , , , , ,